Literature DB >> 24468473

Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.

Jonathan Graff-Radford1, Bradley F Boeve1, Melissa E Murray2, Tanis J Ferman3, Nirubol Tosakulwong4, Timothy G Lesnick4, Mandie Maroney-Smith5, Matthew L Senjem5, Jeffrey Gunter5, Glenn E Smith6, David S Knopman1, Clifford R Jack5, Dennis W Dickson2, Ronald C Petersen1, Kejal Kantarci7.   

Abstract

Magnetic resonance spectroscopy (MRS) characteristics of dementia with Lewy bodies (DLB) Alzheimer's disease (AD) and cognitively normal controls were compared. DLB (n = 34), AD (n = 35), and cognitively normal controls (n = 148) participated in a MRS study from frontal, posterior cingulate, and occipital voxels. We investigated DLB patients with preserved hippocampal volumes to determine the MRS changes in DLB with low probability of overlapping AD pathology. DLB patients were characterized by decreased N-acetylaspartate/creatine (NAA/Cr) in the occipital voxel. AD patients were characterized by lower NAA/Cr in the frontal and posterior cingulate voxels. Normal NAA/Cr levels in the frontal voxel differentiated DLB patients with preserved hippocampal volumes from AD patients. DLB and AD patients had elevated choline/creatine, and myo-Inositol/creatine in the posterior cingulate. MRS abnormalities associated with loss of neuronal integrity localized to the occipital lobes in DLB, and the posterior cingulate gyri and frontal lobes in AD. This pattern of MRS abnormalities may have a role in differential diagnosis of DLB and in distinguishing DLB patients with overlapping AD pathology.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dementia with Lewy bodies; Magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2014        PMID: 24468473      PMCID: PMC3961495          DOI: 10.1016/j.neurobiolaging.2014.01.001

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  48 in total

1.  Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T.

Authors:  P G Antuono; J L Jones; Y Wang; S J Li
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

3.  Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia.

Authors:  V J Kattapong; W M Brooks; M H Wesley; P W Kodituwakku; G A Rosenberg
Journal:  Arch Neurol       Date:  1996-07

4.  Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.

Authors:  N Schuff; A A Capizzano; A T Du; D L Amend; J O'Neill; D Norman; J Kramer; W Jagust; B Miller; O M Wolkowitz; K Yaffe; M W Weiner
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

5.  Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults.

Authors:  Kejal Kantarci; V Lowe; S A Przybelski; M L Senjem; S D Weigand; R J Ivnik; R Roberts; Y E Geda; B F Boeve; D S Knopman; R C Petersen; C R Jack
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

6.  Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients.

Authors:  L L Chao; N Schuff; J H Kramer; A T Du; A A Capizzano; J O'Neill; O M Wolkowitz; W J Jagust; H C Chui; B L Miller; K Yaffe; M W Weiner
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

7.  Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy.

Authors:  D E Saunders; F A Howe; A van den Boogaart; J R Griffiths; M M Brown
Journal:  J Magn Reson Imaging       Date:  1999-05       Impact factor: 4.813

8.  Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease.

Authors:  Noriaki Hattori; Kazuo Abe; Saburo Sakoda; Tohru Sawada
Journal:  Neuroreport       Date:  2002-01-21       Impact factor: 1.837

9.  A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.

Authors:  M Yoshita; J Taki; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

10.  Reduced hippocampal glutamate in Alzheimer disease.

Authors:  R Rupsingh; M Borrie; M Smith; J L Wells; R Bartha
Journal:  Neurobiol Aging       Date:  2009-06-06       Impact factor: 4.673

View more
  11 in total

Review 1.  Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.

Authors:  Tao Song; Xiaopeng Song; Chenyawen Zhu; Regan Patrick; Miranda Skurla; Isabella Santangelo; Morgan Green; David Harper; Boyu Ren; Brent P Forester; Dost Öngür; Fei Du
Journal:  Ageing Res Rev       Date:  2021-10-29       Impact factor: 10.895

2.  Cerebellar Abnormalities on Proton MR Spectroscopy and Imaging in Patients With Gluten Ataxia: A Pilot Study.

Authors:  Vishwa Rawat; Ritu Tyagi; Inder Singh; Prasenjit Das; Achal Kumar Srivastava; Govind K Makharia; Uma Sharma
Journal:  Front Hum Neurosci       Date:  2022-05-17       Impact factor: 3.473

3.  MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease.

Authors:  Bing Zhang; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Mandie Maroney-Smith; Anthony J Spychalla; David S Knopman; Clifford R Jack; Ronald C Petersen; Kejal Kantarci
Journal:  J Neuroimaging       Date:  2014-07-15       Impact factor: 2.486

Review 4.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

5.  Frontal lobe 1H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers.

Authors:  Qin Chen; Bradley F Boeve; Nirubol Tosakulwong; Timothy Lesnick; Danielle Brushaber; Christina Dheel; Julie Fields; Leah Forsberg; Ralitza Gavrilova; Debra Gearhart; Dana Haley; Jeffrey L Gunter; Jonathan Graff-Radford; David Jones; David Knopman; Neill Graff-Radford; Ruth Kraft; Maria Lapid; Rosa Rademakers; Jeremy Syrjanen; Zbigniew K Wszolek; Howie Rosen; Adam L Boxer; Kejal Kantarci
Journal:  Neurology       Date:  2019-07-17       Impact factor: 11.800

6.  Thalamic Involvement in Fluctuating Cognition in Dementia with Lewy Bodies: Magnetic Resonance Evidences.

Authors:  Stefano Delli Pizzi; Raffaella Franciotti; John-Paul Taylor; Astrid Thomas; Armando Tartaro; Marco Onofrj; Laura Bonanni
Journal:  Cereb Cortex       Date:  2014-09-26       Impact factor: 5.357

7.  Does Prefrontal Glutamate Index Cognitive Changes in Parkinson's Disease?

Authors:  Isabelle Buard; Natalie Lopez-Esquibel; Finnuella J Carey; Mark S Brown; Luis D Medina; Eugene Kronberg; Christine S Martin; Sarah Rogers; Samantha K Holden; Michael R Greher; Benzi M Kluger
Journal:  Front Hum Neurosci       Date:  2022-04-12       Impact factor: 3.473

8.  Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.

Authors:  L Su; A M Blamire; R Watson; J He; L Hayes; J T O'Brien
Journal:  Transl Psychiatry       Date:  2016-08-30       Impact factor: 6.222

9.  Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS 1H NMR.

Authors:  Yuzhong Zhang; Zhou Liu; Bing Ji; Lijian Liu; Shaoxiong Wu; Xiaowu Liu; Silun Wang; Liya Wang
Journal:  Front Aging Neurosci       Date:  2019-01-09       Impact factor: 5.750

10.  Application of 1H-MRS in end-stage renal disease with depression.

Authors:  Jiachen Wang; Tong Zhou; Jihua Liu; Jingjun Shangguan; Xuejun Liu; Zhiming Li; Xiaoming Zhou; Yande Ren; Chengjian Wang
Journal:  BMC Nephrol       Date:  2020-06-15       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.